The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Elritercept and luspatercept for anemia in myelofibrosis: efficacy, safety and ongoing trials
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, reviews elritercept and luspatercept for anemia in myelofibrosis. Dr Harrison highlights the transfusion, spleen, symptom and platelet outcomes from the Phase II RESTORE study (NCT05037760) of elritercept, the design of the ongoing Phase III ELRISE-MF trial (NCT07623161), and outcomes from the Phase III INDEPENDENCE trial (NCT04717414) evaluating luspatercept. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
